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Abstract
Background: With the marked increase in the prevalence of diabetes mellitus, it was the purpose of our study to
assess a potential association of time-cumulated exposure to systolic (CumSBP) and of diastolic blood pressure
(CumDBP) with onset of impaired glucose tolerance and diabetes mellitus.
Methods: The prospective investigation included participants of the longitudinal Kailuan Study with three baseline
examinations in 2006–2007, 2008–2009 and 2010–2011, re-examination in 2012–2013, and no diabetes mellitus at
baseline. Cumulative blood pressure (BP) was calculated as cumBP = [(BP1 + BP2)/2 × time1–2] + [(BP2 + BP3)/2 × time2–3].
Based on cumSBP, the study population was stratified into four groups (cumSBP < 480mmHgxyear;n = 15,339;
480mmHgxyear ≤ cumSBP < 520mmHgxyear;n = 7214; 520mmHgxyears ≤ cumSBP < 560mmHgxyears;n = 5675; and
cumSBP ≥ 560mmHgxyears;n = 10,576).
Results: After adjusting for demographic, anthropomorphic, biochemical, socioeconomic and lifestyle parameters and
as compared with the first group, the second, third and fourth group showed a significantly higher incidence of
diabetes (P-trend < 0.001;hazard ratio (HR);95% confidence interval (CI):1.28(1.08,1.51),1.54(1.29,1.84), and 2.33(1.98,2.73),
respectively), higher incidence of impairment of glucose tolerance (P-trend < 0.001;HR;95% CI1.17(1.02,1.33),
1.43(1.25,1.64), and 2.09(1.85,2.37), respectively), and higher incidence of diabetes developing out of an impairment of
glucose tolerance (P-trend < 0.001;HR;95% CI:1.22(0.97,1.54),1.47(1.16,1.86), and 2.01(1.62,2.50), respectively). An increase in
cumSBP by 10 mmHg/year or an increase in cumDBP by 5 mmHg/year was associated with a hazard ratio of incident
diabetes of 1.04 (95% CI:1.03,1.04) and 1.02(1.02,1.03), respectively, with a hazard ratio of incident impairment of glucose
tolerance of 1.04(95% CI:1.03,1.04) and 1.03(95% CI:1.02,1.03), respectively, and with a hazard ratio of incident
diabetes developing from impairment of glucose tolerance of 1.04(95% CI:1.03,1.04) and 1.03(95% CI:1.02,1.03), respectively.
Conclusions: Time-cumulated exposure to elevated blood pressure was significantly associated with an elevated incidence
of impaired glucose tolerance and diabetes.
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Background
According to the recent Global Burden of Disease Study
2015, diabetes mellitus has become one of the most
common causes for disability and premature death [1, 2].
Major sequelae of diabetes include an increased risk of
arterial hypertension among other disorders such as car-
diovascular diseases and cerebrovascular events [3, 4].
Previous studies suggested that hypertension may vice
versa increase the risk of developing diabetes mellitus,
while other studies contradicted such a relationship [5–9].
One of the reasons for the discrepancy between the stud-
ies may have been that most of the studies did not assess
blood pressure in a longitudinal manner so that the cumu-
lative exposure to blood pressure could not be taken into
account. Cumulative exposure to a risk factor as com-
pared to a time point-related measurement of the risk fac-
tor may however be a more precise parameter if the
potential associations of the risk factor are assessed. To
cite examples, the prospective study by the U.K. Prospect-
ive Diabetes Study Group was one of the first to suggest
that the cumulative exposure to elevated glucose serum
concentrations increased the risk of diabetes-related com-
plications [10]. Navar-Boggan and colleagues showed that
the cumulative exposure to hyperlipidemia increased the
incidence of coronary heart diseases [11]. A study by
Zemaintis and associates revealed that a high cumulative
blood pressure exposure was related with an increased
risk of renal complications [12]. Since only few studies
have so far been focused on the association between cu-
mulative blood pressure exposure and incident diabetes or
incident glucose tolerance impairment, we conducted this
study and analyzed the relationship between cumulative
blood pressure exposure and both diabetes-related param-
eters in the Kailuan Study.
Methods
The community of Kailuan in Tangshan in the Chinese
province of Hebei was the site for the Kailuan study
which has been a prospective cohort study registered
under No. #: ChiCTR-TNC-11001489. An informed
consent was signed by all study participants and the
Ethics Committees of Kailuan General Hospital ap-
proved the investigation. The study included employees
and retirees of a coal mine company (Kailuan Group
Company). At baseline, the study population consisted
of 101,510 individuals with an age ranging between
18 years and 98 years. The study participants were re-
peatedly and prospectively examined in two-years inter-
vals [13–15].
Trained interviewers asked the study participants ques-
tions focusing on the socioeconomic background, physical
activity, diet, and known systemic diseases. Blood pres-
sure, body height, body weight and hip and waist circum-
ference were measured and electrocardiography and an
ultrasound examination of the pancreas, spleen, kidney,
liver, gallbladder, abdomen and breast were carried out.
The serum concentration of glucose, high-density lipopro-
teins, low-density lipoproteins and triglycerides was deter-
mined in blood samples taken under fasting conditions.
We measured the blood pressure between 7 am and 9 am
at the same day when all other examinations were per-
formed. Before the blood pressure measurements were
taken, the individuals had to sit in a relaxed manner for at
least 15 min and had to have refrained from taking tea or
coffee and from smoking for at least half an hour. Using a
mercury sphygmomanometer, blood pressure was mea-
sured at the right upper arm, with the measurement being
repeated twice in intervals of 2 min. We took the mean of
all three measurements for further statistical analysis.
The cumulative exposure to blood pressure was calcu-
lated by multiplying the exposure doses with exposure
time, i.e., cumulative blood pressure (cumBP) = [(BP1 + BP2)
/ 2 x time1–2] + [(BP2 + BP3) /2 x time2–3], where BP1,
BP2 and BP3 were the blood pressure measured at the
first, second and third physical examination, respectively;
time1–2 and time2–3 meant the interval between the two
blood pressure determinations [11]. cumBP was differ-
entiated between the cumulative systolic blood pres-
sure (cumSBP) and the cumulative diastolic blood
pressure (cumDBP).
The definition of current smoking consisted of inhal-
ation of at least one cigarette daily during the preceding
year, and consumption of alcohol was defined as the
daily intake of at least 50 mL of alcohol daily during the
last year. Individuals were considered to carry out phys-
ical exercise if they weekly performed three or more
exercises of at least half an hour. A fasting serum
glucose concentration of ≥7.0 mmol/L, history of dia-
betes or current therapy of diabetes with intake of
blood glucose-lowering drugs were the criteria for the
diagnosis of diabetes mellitus. A fasting serum con-
centration of glucose of ≥6.1 mmol/L and <7.0 mmol/
L without history of diabetes and without blood-
glucose lowering therapy formed the definition of an
impairment of the glucose tolerance.
Inclusion criteria for the current investigation were
participation in the baseline examinations in the years
2006–2007, 2008–2009 and 2010–2011, and in the
follow-up examination in 2012–2013; an age of ≥18 years
at the first baseline examination; and available blood
pressure measurements and measurements of the
diabetes-related parameters data from all four examina-
tions. Exclusion criterion was the diagnosis of diabetes
(i.e., history of diabetes or currently taking hypoglycemic
drugs or a fasting serum glucose concentration of ≥7.0
at any of the three baseline examinations).
For the statistical analysis we used the first three
examinations performed in 2006–2007, 2008–2009 and
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2010–2011 as baseline examinations, and the follow-up
period was the time of the third baseline examination
and the fourth examination in the period from 2010 to
2011. Endpoint events were the development of an im-
pairment of glucose tolerance without previously de-
tected impairment of glucose tolerance, the development
of diabetes without previously detected diabetes, and the
incidence of diabetes developing from an impairment of
glucose tolerance. The measurements were presented as
mean ± standard deviations. First, we carried out a uni-
variate analysis of the associations of incident impair-
ment of glucose tolerance or of incident diabetes with
other parameters. The cumulative incidence of the end-
point events, i.e. development of an impairment of
glucose tolerance or development of diabetes, in de-
pendence of the cumSBP and cumDBP was calculated
using the life-cycle method. The difference in the inci-
dence of the endpoint events was compared with the
Log-rank test. Hazard ratios (HR) and their 95% confi-
dence intervals (CI) were calculated by the Cox propor-
tion hazard model and natural spline function. A result
was considered to be statistically significant if P-value
was less than 0.05 (two-sided test).
Results
Out of 101,510 individuals participating in the baseline
examination of the Kailuan Study, 15,008 subjects were
excluded since they already had a diagnosis of diabetes
prior to the examination in the period from 2012 to
2013. Due to missing or incomplete follow-up examina-
tions, we additionally excluded 47,698 individuals, so
that eventually a total of 38,804 participants were in-
cluded into the current analysis. For the examination of
the relationship between cumBP and glucose tolerance
impairment, we included 31,935 participants who did
not show glucose tolerance impairment in 2006, 2008 or
2010. For the assessment of the association between
cumBP and risk of converting from glucose tolerance
impairment to diabetes, we included the remaining 6869
participants who showed glucose tolerance impairment
at the examinations in the periods of 2006 to 2007, 2008
to 2009 or 2010 to 2011 (Fig. 1).
The individuals included into the current analyses as
compared to the individuals excluded due to missing or
incomplete follow-up examinations were significantly
(P ≤ 0.001) younger, had a higher level of education, a
higher concentration of high-density lipoproteins, a
lower resting heart rate, systolic blood pressure and dia-
stolic blood pressure, lower concentration of fasting
blood glucose, total cholesterol, low-density lipoproteins,
high-sensitive C-reactive protein and uric acid, and a
lower prevalence of male gender, performing of phys-
ical exercise and intake of pressure-lowering drugs
(Additional file 1: Table S1).
The mean age of the study participants (n = 38,804 (29,129
(75.1%) men)) was 47.8 ± 11.7 years (Additional file 1:
Table S1). The whole study population was stratified
into four groups based on the cumSBP. The first
Fig. 1 Scheme showing the inclusion and exclusion of study participants
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group included 15,339 individuals with a cumSBP of
<480 mmHg x year (120 mmHg × 4 years), the sec-
ond group consisted of 7214 subjects with a cumSBP
≥480 mmHg x year and <520 mmHgxyear (or
130 mmHg × 4 years), the third group included 5675
participants with a cumSBP ≥520 mmHg x years and
<560 mmHg x years (or 140 mmHg × 4 years), and
the fourth group consisted of 10,576 individuals with
a cumSBP ≥560 mmHg x years (Table 1). Compared
with the first group, the second, third and fourth
group showed a significantly (P ≤ 0.001) higher per-
centage of male gender, older age, higher heart rate,
higher body mass index, higher serum concentration of
glucose, total cholesterol, high-density lipoproteins, low-
density lipoproteins, uric acid, triglycerides, and high-
sensitive C-reactive protein, higher prevalence of smoking
and alcohol consumption, higher prevalence of physical
exercise, and higher prevalence of blood pressure lowering
drugs, and lower level of education (Table 1).
Within a follow-up period of 2.22 ± 0 38 years after
the third baseline examination of 2010–2011, 1523
(3.9%) individuals out of the 38,804 participants without
diabetes (with or without glucose tolerance impairment)
at the baseline examinations newly developed diabetes
mellitus; 2563 (8.0%) individuals out of the 31,935 par-
ticipants without impairment of glucose tolerance and
without diabetes at the baseline examinations newly de-
veloped an impaired glucose tolerance; and 874 (12.7%)
individuals out of 6869 participants with impaired glu-
cose tolerance newly developed diabetes mellitus. The
risk of an incident impairment of glucose tolerance and
of incident diabetes significantly increased with in-
creasing cumulative blood pressure exposure as indi-
cated by an increasing group number of the stratified
study population (Additional file 2: Table S2; Tables 2
and 3) (Fig. 2).
We then applied a Cox proportion risk model with the
incidence of an impaired glucose tolerance or incidence
of diabetes as dependent variable and with cumSBP and
cumDBP as independent variables. In a model 1, we
adjusted for gender and age; in model we additionally
adjusted for smoking, alcohol consumption, amount of
physical exercises, level education and taking of blood
pressure-lowering drugs; and in model, we additionally
Table 1 Characteristics (Mean ± Standard deviation) of the study participants stratified by the cumulative systolic blood pressure
Variables Total population
(n = 38,804)
Group 1
(n = 15,339)
Group 2
(n = 7214)
Group 3
(n = 5675)
Group 4
(n = 10,576)
P-value
Cumulative Systolic Blood Pressure
(mmHg x year)
<480 ≥480 and <520 ≥520 and <560 ≥560
Men (n) 29,129 (75.1%) 10,461 (68.2%) 5813 (80.6%) 4528 (79.8%) 8327 (78.7%) <0.001
Age (Years) 47.82 ± 11.70 41.96 ± 9.75 46.54 ± 10.38 50.16 ± 10.64 55.94 ± 10.51 <0.001
Heart Rate (Beats/min) 73.03 ± 9.69 72.46 ± 9.16 73.26 ± 9.64 73.26 ± 9.86 73.58 ± 10.32 <0.001
Systolic Blood Pressure (mmHg) 126.9 ± 19.3 115.1 ± 12.7 125.4 ± 13.7 130.9 ± 15.9 143.1 ± 19.8 <0.001
Diastolic Blood Pressure (mmHg) 82.1 ± 11.2 76.4 ± 8.8 82.1 ± 9.4 84.4 ± 10.3 88.9 ± 11.7 <0.001
Body Mass Index (kg/m2) 24.89 ± 3.42 24.08 ± 3.31 25.06 ± 3.34 25.35 ± 3.39 25.71 ± 3.39 <0.001
Fasting Serum Concentration of
Glucose (mmol/L)
5.01 ± 0.65 4.96 ± 0.62 5.05 ± 0.65 5.04 ± 0.66 5.02 ± 0.68 <0.001
Total Cholesterol (mmol/L) 4.89 ± 1.11 4.75 ± 1.05 4.87 ± 1.15 4.96 ± 1.14 5.07 ± 1.14 <0.001
High-Density Lipoproteins (mmol/L) 1.55 ± 0.39 1.54 ± 0.37 1.54 ± 0.38 1.57 ± 0.42 1.57 ± 0.42 <0.001
Low-Density Lipoproteins (mmol/L) 2.29 ± 0.89 2.26 ± 0.82 2.33 ± 0.86 2.30 ± 0.91 2.30 ± 1.01 <0.001
Uric Acid Concentration (μmol/L) 284.7 ± 82.1 270.6 ± 77.3 284.0 ± 79.6 288.5 ± 81.3 303.3 ± 86.8 <0.001
Triglycerides (Median (Q1,Q3)) 1.23 (0.86, 1.84) 1.12 (0.78, 1.63) 1.26 (0.89, 1.89) 1.31 (0.93, 1.98) 1.35 (0.96, 2.02) <0.001
High-Sensitive C-Reactive Protein
(Median (Q1,Q3))
0.70 (0.27, 1.96) 0.60 (0.20, 1.50) 0.69 (0.25, 1.90) 0.70 (0.30, 2.02) 0.96 (0.38, 2.60) <0.001
Smoking (n) 11,616 (29.9%) 4423 (28.8%) 2359 (32.7%) 1772 (31.2%) 3062 (29.0%) <0.001
Drinking (n) 6608 (17.0%) 1986 (12.9%) 1323 (18.3%) 1076 (19.0%) 2223 (21.0%) <0.001
Exercise (n) 5212 (13.4%) 1244 (8.1%) 779 (10.8%) 831 (14.6%) 2358 (22.3%) <0.001
Pressure-lowering drugs (n) 3211 (8.3%) 226 (1.5%) 292 (4.0%) 464 (8.2%) 2229 (21.1%) <0.001
Education: Illiteracy / Primary (n) 2655 (6.8%) 473 (3.1%) 404 (5.6%) 426 (7.5%) 1352 (12.8%) <0.001
Junior High School (n) 26,706 (68.8%) 10,294 (67.1%) 5093 (70.6%) 4083 (71.9%) 7236 (68.4%)
High School (n) 6264 (16.1%) 2864 (18.7%) 1158 (16.1%) 818 (14.4%) 1424 (13.5%)
College or Higher (n) 3179 (8.2%) 1708 (11.1%) 559 (7.7%) 348 (6.1%) 564 (5.3%)
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adjusted for heart rate, body mass index, and fasting
serum concentrations of glucose, triglycerides, high-
sensitive C-reactive protein, high-density lipoproteins,
low-density lipoproteins and uric acid. The Cox propor-
tion risk model revealed that an increase in cumSBP by
10 mmHg/year or an increase in cumDBP by 5 mmHg/
year was associated with a hazard ratio of incident dia-
betes of 1.04 (95% CI: 1.03, 1.04) and 1.02 (95% CI: 1.02,
1.03), respectively. The same increases in cumSBP and
in cumDBP were associated with a hazard ratio of in-
cident impairment of glucose tolerance of 1.04 (95%
CI: 1.03, 1.04) and 1.03 (95% CI: 1.02, 1.03), respect-
ively. The same increases in cumSBP and in cumDBP
were associated with a hazard ratio of incident dia-
betes developing from an impairment of glucose tol-
erance of 1.04 (95% CI: 1.03, 1.04) and 1.03 (95% CI:
1.02, 1.03), respectively (Additional file 2: Table S2;
Tables 2 and 3).
Discussion
The prospective Kailuan Study showed that the exposure
to elevated blood pressure accumulated over 3 examina-
tions performed in 5 years was significantly associated
with an increased incidence of diabetes, within the sub-
group of individuals without previously impaired glucose
tolerance and within the subgroup of individuals with
previously impaired glucose tolerance. In a parallel man-
ner, a higher accumulated exposure to elevated blood
pressure was correlated with a higher rate of newly devel-
oped impairment of glucose tolerance (Additional file 2:
Table S2; Tables 1, 2 and 3). For each increase in the
cumSBP by 10 mmHg/year the risk of incident diabetes
and of incident impairment of glucose tolerance increased
by 3%. In multivariate analysis, this increase was inde-
pendent of other diabetes-related related risk factors such
as older age, gender, smoking, alcohol consumption,
amount of physical exercise, level education and taking
Fig. 2 a Development of Impairment of Glucose Tolerance in 2563 (8.0%) Individuals out of 31,935 Participants Without Impairment of Glucose
Tolerance and Without Diabetes at the Baseline Examinations. b Development of New-Onset of Diabetes in 874 (12.7%) Individuals out of 6869
Participants with Impaired Glucose Tolerance at the Baseline Examinations
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blood pressure-lowering drugs, and heart rate, body mass
index, and fasting serum concentrations of glucose, tri-
glycerides, high-sensitive C-reactive protein, high-density
lipoproteins and low-density lipoproteins and uric acid.
The findings obtained in our study were in agreement
with the results found in previous investigations. In a
study Emdin and colleagues on more than 4 million
adults, an increase in systolic blood pressure by
20 mmHg was correlated with a 58% higher risk of de-
veloping diabetes, and an increase in diastolic blood
pressure by 10 mmHg was correlated with a 52% higher
chance to develop diabetes [7]. The association between
blood pressure and the incidence of diabetes mellitus
(type 2) was also examined by Hayashi and colleagues
[5] In a prospective study on more than 7000 Japanese
men with an age ranging between 35 years and 60 years,
high normal blood pressure as compared with normal
blood pressure was associated with a 39% higher risk,
and arterial hypertension was associated with a 76%
higher risk, to develop diabetes mellitus. In the Cande-
sartan Antihypertensive Survival Evaluation in the Japan
trial on high-risk Japanese hypertensive patients, Yasuno
and associates found that for each standard deviation in-
crease in pulse pressure the hazard ratio for the develop-
ment of diabetes was 1.44 in a multiple regression
analysis [6]. A longitudinal investigation performed by
Stahl and coworkers included more than 7000 men who
were free of diabetes and who were followed-up for
35 years [16]. The hazard ratio for the incidence of dia-
betes was 1.43, 1.43 and 1.95 for individuals with a
systolic blood pressure of 130–139 mmHg, 140–
159 mmHg, and ≥160 mmHg, respectively, while a sys-
tolic blood pressure of less than 130 mmHg served as
reference level. Analyzing the data of the Atherosclerosis
Risk in Communities study, the Coronary Artery Risk
Development in Young Adults study and the Framingham
Heart Study offspring cohort together, Wei and colleagues
found that the age-adjusted incidence of type 2 diabetes
was increasingly higher across increasing blood pressure
groups [17]. In contrast to the studies mentioned above,
blood pressure factors was not predictive for incident
diabetes in a study by Norberg and associates, whose
investigation was a case-referent study nested within
a population-based health survey [8]. In a similar
manner in the investigation by Wang and colleagues,
systolic and diastolic blood pressure did not predict
the onset of diabetes [9].
Our study adds to the current knowledge on the asso-
ciation between hypertension and the development of
diabetes and an impairment of glucose tolerance by tak-
ing into account the time-cumulative exposure to an in-
creased blood pressure over a relatively long time of
5 years as baseline values, and by also addressing the de-
velopment of an impairment of glucose tolerance.
Studies on the associations between the time-cumulative
exposure to risk factors for the incidence of major
diseases have so far been performed with respect to
the cumulative data on hyperglycemia and diabetic
complications, the cumulative exposure to high serum
concentrations of cholesterol and the incidence of
coronary heart disease, and to the cumulative blood
pressure exposure and the development of kidney
damage [10–12].
The reasons for the association between time-
cumulated blood pressure exposure and incident impair-
ment of glucose tolerance and incident diabetes mellitus
have remained elusive so far. Previous studies have
shown that a low-grade inflammatory process occurs in
both diabetes and hypertension both of which could be
considered as chronic inflammatory diseases [18–21].
Correspondingly, inflammatory markers such as C-
reactive protein are increased in patients with diabetes
and in patients with arterial hypertension and do also
predict the development of these diseases [22, 23]. Gene
regulatory network analysis has demonstrated that oxi-
dative stress is important for diabetes and hypertension,
with the oxidative stress-mediated regulation cascade be-
ing the common mechanistic link among the pathogen-
esis of diabetes, arterial hypertension, and other related
inflammatory diseases [24]. Also, insulin as a pleiotropic
hormone plays a pivotal role in the development of
arterial hypertension and diabetes.
In view of the pronounced increase in the prevalence
of diabetes and arterial hypertension, the search of new
screening tools that are economic and easily available in
the clinical practice is of high practical importance. To
date, several markers have been available to indicate an
increased risk for the onset and progression of diabetes,
such as inflammatory markers or proinsulin/insulin ra-
tio, however they are not easily feasible for large scale
screening [25, 26]. Furthermore, early identification of
diabetes may be useful in terms of lifestyle intervention
and prevention of long term complications. The results
of the present study suggest that the time-cumulated ex-
posure to elevated blood pressure is an additional risk
factor predicting an increased likelihood to develop an
impaired glucose tolerance and diabetes. Time-cumulated
exposure to elevated blood pressure in combination with
other parameters such as inflammatory markers, the pro-
insulin/insulin ratio, body mass index and amount of
physical activity may be taken in a synopsis to estimate
the risk of eventual onset of diabetes.
Limitations of our study should be discussed. First, the
follow-up period of 2.22 years after the baseline period
of 5 years was relatively short. With a longer follow-up
and a higher number of patients developing diabetes or
an impairment of glucose tolerance, the statistical sig-
nificance of the associations between hypertension and
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the incidence might have become even clearer. Second,
it has remained elusive, whether the multivariate analysis
with adjustment for a multitude of parameters (including
gender, age, smoking, alcohol consumption, amount of
physical exercises, level education, taking of blood
pressure-lowering drugs, heart rate, body mass index
and fasting serum concentrations of glucose, triglycer-
ides, high-sensitive C-reactive protein, high-density lipo-
proteins and low-density lipoproteins and uric acid) had
not overlooked an additional factor potentially con-
founding the associations between hypertension and
incidence of diabetes and impairment of glucose toler-
ance. In view of the robust statistical significance of
these associations however, it might have been unlikely
that a factor besides those already taken into account
might have markedly impeded the associations between
hypertension and incidence of diabetes and impairment
of glucose tolerance as found in our study.
Conclusions
Time-cumulated exposure to elevated blood pressure
was significantly associated with an elevated incidence of
impaired glucose tolerance and diabetes, after adjusting
for serum concentration of glucose and other diabetes-
related parameters. Diabetes mellitus may be included
into the list of sequelae of arterial hypertension. Future
studies may address whether therapeutic lowering of ele-
vated blood pressure may prevent or delay the onset of
impaired glucose tolerance and diabetes.
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